Belite Bio Inc

Last updated September 27, 2026

Organization details

Legal name
Belite Bio Inc
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Cayman Islands
Headquarters city
SAN Diego
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
BLTE
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001889109

Board of directors

Chief executives

Yu-Hsin Lin · Chief Executive Officer
Since March 2026

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$40,957,466
179 sales by 5 insiders
Date Insider Transaction Shares Price Value
Nov 12, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −500 $162.04 $81,020
Nov 12, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −500 $164.68 $82,342
Nov 12, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −500 $166.82 $83,410
Nov 12, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −500 $170.41 $85,205
Oct 29, 2026 Yu-Hsin Lin Director, Officer (Chief Executive Officer) Other +5,000 — —
Oct 29, 2026 Hao-Yuan Chuang Director, Officer (Chief Financial Officer) Other +5,000 — —
Oct 1, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −200 $163.63 $32,725
Oct 1, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −24 $164.64 $3,951
Oct 1, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −120 $165.49 $19,859
Oct 1, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −50 $166.44 $8,322
Oct 1, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −78 $167.59 $13,072
Oct 1, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −12 $168.21 $2,019
Oct 1, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −14 $169.36 $2,371
Oct 1, 2026 Scholl Hendrik Peter Officer (Chief Medical Officer) Open-market sale −2 $170.02 $340
Sep 24, 2026 Wan-Shan Chen Director In-the-money exercise +13,796 $0.44 $6,051

Organizations in the same sector, closest in location and size first.

Questions about Belite Bio Inc

Who is the CEO of Belite Bio Inc?

Yu-Hsin Lin has been Belite Bio Inc's Chief Executive Officer since March 2026.

How many directors are on Belite Bio Inc's board?

Belite Bio Inc's board has 7 directors: Gary Clark Biddle, Hao-Yuan Chuang, Ita Lu, John Michael Longo, Wan-Shan Chen, Xiao-Hui Chen and Yu-Hsin Lin.

Are Belite Bio Inc insiders buying or selling shares?

Over the last 12 months, Belite Bio Inc insiders made no open-market purchases and sold $41.0 million of shares in 179 sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="belite-bio-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.